BVX-0922 / BioVaxys - LARVOL DELTA

BioVaxys Expands Cancer Vaccine Platform (Canada Newswire) - "BioVaxys Technology Corp....announced today the expansion of its cancer vaccine platform with BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer ('CRC'). BioVaxys plans to advance an Investigator-Sponsored Clinical Trial Application ('CTA') in the EU with the European Medicines Agency ('EMEA') this year for BVX-0922. An Investigator Sponsored CTA is submitted to regulatory authorities by a clinical investigator who both initiates and conducts an initial clinical study of a new drug or procedure, and under whose immediate direction the investigational drug is administered. "

Clinical • European regulatory • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor